Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | exonuclease III APE | 0.0018 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0073 | 0.3089 | 0.3089 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0018 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.1684 | 0.545 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0018 | 0 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0073 | 0.3089 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0018 | 0 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0048 | 0.1684 | 0.545 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0018 | 0 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0196 | 1 | 1 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0018 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0073 | 0.3089 | 0.3089 |
Schistosoma mansoni | hypothetical protein | 0.0196 | 1 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0048 | 0.1684 | 0.545 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0033 | 0.0823 | 0.2664 |
Brugia malayi | RNA binding protein | 0.0073 | 0.3089 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0073 | 0.3089 | 0.3089 |
Brugia malayi | TAR-binding protein | 0.0073 | 0.3089 | 1 |
Echinococcus multilocularis | geminin | 0.0196 | 1 | 1 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0018 | 0 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0073 | 0.3089 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0073 | 0.3089 | 0.3089 |
Schistosoma mansoni | tar DNA-binding protein | 0.0073 | 0.3089 | 0.3089 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0033 | 0.0823 | 0.0823 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0018 | 0 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0073 | 0.3089 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0018 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.0823 | 0.2664 |
Echinococcus multilocularis | tar DNA binding protein | 0.0073 | 0.3089 | 0.3089 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0048 | 0.1684 | 0.545 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0018 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0018 | 0 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0073 | 0.3089 | 0.3089 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0073 | 0.3089 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 0.6 nmol | Photocytotoxicity against human HeLa cells assessed as survival-fraction per unit uptake measured as concentration in incubation medium necessary to produce cell uptake of 0.3 nmol per mg of protein at which survival fraction was determined after 24 hrs in presence of 10 J/cm2 light | ChEMBL. | 20441223 |
Drug uptake (ADMET) | = 8.2 nmol | Cellular uptake in human HeLa cells measured per mg of protein at 20.5 uM after 24 hrs by fluorescence measurements | ChEMBL. | 20441223 |
LD50 (functional) | = 2000 nM | Photocytotoxicity against human HeLa cells after 24 hrs by MTT assay in presence of 10 J/cm2 laser | ChEMBL. | 20441223 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.